Why the study?
Does intracoronary infusion of mesenchymal stem cells prevent heart failure in patients with acute myocardial infarction?
Does intracoronary infusion of mesenchymal stem cells prevent heart failure in patients with acute myocardial infarction?
This expression of concern highlights significant data and ethical irregularities in a phase 3 trial of mesenchymal stem cells for post-MI heart failure.
Answers are grounded in this paper and cite their sources.
Undermines validity of the phase 3 mesenchymal stem cell trial in acute MI; leaves efficacy open pending independent reanalysis.
The BMJ was alerted to post-publication discussion raising concerns about a variety of issues; some issues were apparent from the data that support the paper, and are linked to from the article.Examples of the issues identified include irregularities in the data, concern about the inclusion of participants who did not meet the age criteria specified in the study, and concerns about undeclared conflicts of interest and authorship.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: